The JPMA, the overall coordinator of the pharmaceutical industry
The Japan Pharmaceutical Manufacturers Association (JPMA) is a research and development-oriented organization of pharmaceutical companies aimed at contributing to the health and welfare of people in Japan and the rest of the world by creating innovative and highly beneficial pharmaceutical products as well as by promoting the sound development of the pharmaceutical industry.
We extend our sincere condolences and sympathies to those who have been impacted by the Great East Japan Earthquake as well as our heartfelt wishes for the earliest recovery of the areas hit by this disaster. In this regard, we, the pharmaceutical industry, continue to hold it our greatest mission to deliver essential medicines to those in need of them.
The research and development capabilities of the Japanese pharmaceutical industry are high even by the world’s standards, making Japan one of the few countries capable of pharmaceutical innovations. Since the beginning of the new century, remarkable advances have been made in genome research and life sciences, and we intend to draw on these results and the latest technology for creation of innovative pharmaceuticals to continue to advance patient-oriented healthcare. We also intend to proactively address the drug lag issue on drugs that remain unapproved and off-label as one of the most urgent issues to be resolved. In this regard, we are pleased to be able to report that for all developmental drug candidates, relevant pharmaceutical companies with a declared interest in the development of such candidates have indicated that these agents will be covered by insurance or will be made available for clinical use following their regulatory approval. We intend to continue strenuously in this endeavor.
The research and development of pharmaceuticals not only calls for an inordinate amount of time and money but also is associated with an increasingly lower chance of success. In this regard, a drug price system that would allow appropriate evaluation of pharmaceuticals for their intrinsic value is required to contribute to the world’s healthcare and to maintain our competitiveness as a pharmaceutical industry. To this end, the JPMA are working toward realization of the full implementation for the "Premium for promotion of new drug creation and resolution of unapproved drugs/indications" in the drug pricing system, which became effective on a trial basis from the fiscal year 2010.
To promote corporate transparency, the JPMA intends to focus more attention than ever on enforcing appropriate corporate ethics practices and observance of relevant promotion codes among its member companies. Additionally, the JPMA intends to promote understanding and adoption of the newly established "Guidelines for Transparency in Relationships between Corporate Activities and Healthcare Institutions" in collaboration with relevant organizations.
In accordance with the "Life Innovation-based Health-oriented Nation Strategy" as part of the "New Growth Strategy" announced in 2010 by the government, the JPMA plans to offer maximum cooperation in all measures being deployed including those aimed at improving the environment for conducting clinical trials to help accelerate healthcare innovations. To this end, the JPMA intends to advocate as strongly as possible toward the unification of budgets across government ministries and agencies as well as strengthening its playmaker role whereby it encourages the government to implement measures aimed at generating innovation.
Last but not least, the JPMA plans to continue to offer healthcare policy-related recommendations and to implement public relations activities as the industry who contributes to the promotion of health and welfare in the global population.